公开(公告)号：US20160356778A1

公开(公告)日：2016-12-08

申请号：US15170789

申请日：2016-06-01

申请人： Celgene Corporation ,  National University Corporation Oita University

发明人： Hidekatsu IHA ,  Emi IKEBE

IPC分类号： G01N33/574 ,  C12Q1/68 ,  A61K31/454

CPC分类号： G01N33/57484 ,  A61K31/454 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/57426 ,  G01N2333/47 ,  G01N2800/52

摘要： A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering a treatment compound to a subject having cancer; obtaining a sample from the subject; determining the ratio of a first biomarker level to a second biomarker level in the sample from the subject, wherein at least one of the biomarkers is a CRBN-associated protein; and diagnosing the subject as being likely to be responsive to the treatment compound if the ratio of the biomarker levels in the sample of the subject changes as compared to a reference ratio of the biomarker levels.

摘要翻译： 一种识别患有可能对治疗化合物有反应的癌症的受试者的方法，包括向具有癌症的受试者施用治疗化合物; 从受试者获取样本; 确定来自所述受试者的样品中第一生物标志物水平与第二生物标志物水平的比率，其中所述生物标志物中的至少一个是CRBN相关蛋白; 以及如果所述受试者样品中的生物标志物水平与所述生物标志物水平的参考比例相比变化，则将所述受试者诊断为可能对所述治疗化合物有反应。